Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

99.44 +2.74 (+2.83%)
Streaming Delayed Price Updated: 11:58 AM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 519,110
Open 96.39
Bid (Size) 99.31 (100)
Ask (Size) 99.57 (400)
Prev. Close 96.70
Today's Range 95.36 - 99.86
52wk Range 79.52 - 124.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering

Performance

YTD
+2.8%
+2.8%
1 Month
+9.8%
+9.8%
3 Month
-2.7%
-2.7%
6 Month
-2.8%
-2.8%
1 Year
-2.8%
-2.8%

More News

Read More
News headline image
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
From BioNTech SE
Via GlobeNewswire
BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit ↗
Via Chartmill
BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio ↗
Via Stocktwits
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
Why BioNTech Stock Is Getting Crushed Today ↗
Via The Motley Fool
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
Via MarketMinute
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Why Did BNTX Stock Tumble 17% Pre-Market Today? ↗
Via Stocktwits
News headline image
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
From BioNTech SE
Via GlobeNewswire
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
Via Finterra
Topics Intellectual Property
News headline image
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
Via Finterra
Topics Economy Intellectual Property
News headline image
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
Via Finterra
Topics Artificial Intelligence Initial Public Offering Intellectual Property
News headline image
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
From BioNTech SE
Via GlobeNewswire
News headline image
2 Biotech Stocks Set to Rebound in 2026 ↗
Via The Motley Fool
News headline image
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
From USA News Group
Via GlobeNewswire

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 99.44
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 04/14/26 11:58 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.